Jonathan M. Email & Phone Number

• Responsible for the overall operation of the health clinic & assuring compliance with regulations. • Provide Administrative oversight & coordination between staff members & healthcare programs. • Assist in patient intakes, follow-ups, and various performed medical procedures. • Participate in safety and quality assurance programs. for both clinic visits and electroencephalograms (EEG) and electromyograms (EMG')• Prepare reports and financial statistics for budget analysis.• Researched and published patient reading material on the use of THC in the New York state medical marijuana program, including qualifying disorders, like epilepsy and the different THC: CBD ratios.• Researched and published patient reading material on the use of Intravenous Immunoglobulin as either as first-line therapy or adjunctive treatment for Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy.

New York, New York, Us

• Performed DNA sequencing for Single Nucleotide Polymorphisms (SNPs) (i.e. genetic variations in human DNA) via NGS• Created an initial database of SNPs for “diet, lifestyle, & exercise” database with a 20% in physician/patient usage.• Researched and translated peer-reviewed scientific articles on gene mutations for accuracy & utility into the NAG database. • Researched and advocated for incorporating biomarkers and genomics into personalized medicine, using SQL and Python

Chicago, Illinois, Us

• Medical assistant and transcriptionist, completing and coordinating patient notes in coordination with HIPAA rules.• Completed Subject Objective Assessment Plan notes and used ICD-10 coding to enter billing into EMR systems.• Educated patients on potential progression of pathology and the importance of medication compliance, and MOA.

Chicago, Illinois, Us

• Performed Mental Status Exam• PHQ-9 & HAM-D• Asses ADHD Self-Reporting

Chicago, Illinois, Us

• Educating patients on Novel Oral Anticoagulants versus Heparin and Coumadin• Familiarity with FDA regulations of Clinical Trials for patients suffering from certain cancers.• Enhancing my knowledge of Chemotherapeutic Agents and side effect profiles including Antineoplastics; Antimetabolites, Alkylating agents, Nitrosoureas, Vinka Alkaloids, and Novel Biologics (Therapeutic Antibodies)• Drugs include Lupron in the treatment of prostate ca, Marinol, Venclexta, Empliciti, Imbruvica

Chicago, Il, Us

• Performed translational researchPharmacokinetics: Bioavailability, Volumes of Distribution, Clearance rates, Half-life, Dosage calculations, Eliminations (“0” order vs 1st order), Urine pH and Drug Elimination, Phases 1 (P-450) and 2 Drug Metabolism, Prodrug Metabolism, and using Relative Efficacy and Potency calculations and graphs• Using real world application of Enzyme Kinetics (Competitive vs Non-competitive Inhibition)

New York, Ny, Us

• Completed a comprehensive 4-step literature review on “The Effect of HIV Infection and HAART on Oral Microbial Colonization” which served as the foundation for multiple subsequent publications.• Created Trial Master Files for Clinical Trials.• Performed grant writing; successfully communicated with an Institutional Review Board (IRB) & Ethics Committee (EC) protecting human subjects and assuring compliance with state and federal regulations• Studied diagnostic markers, epigenetic mechanisms of infection, and presented translational research.• Practiced standard cell preparation, protein isolation purification, and separation and stability analysis.• Published Article: Current HIV/AIDS Report. “Human microbiome and HIV/AIDS.” 2012, March 9th

New York, New York, Us

• Organized data of 51,000 patients, related to “Major Bleeding Events” for Meta-Analysis of 52 clinical trials. • Calculated incidence rates and Kaplan-Meier survival analysis among patients with upper and lower GI adverse events (hemorrhage, obstruction, perforation, etc.) with effect size related to Celebrex. • Evaluated and compared the efficacy and safety of recent FDA approved COX-1, 2 & COX-2 selective inhibitors.• Presented data and analysis from R & D to Health Outcomes & Economics Research and Quality Control. • Developed a first-hand understanding of pharmaceutical FDA & EMA regulations & pharmacovigilance practices.• Analyzed Rheumatology study protocols, case report forms, current IISR studies, with ICH-GCP & CTD.• Medical writing including regulatory-related documents, drug-related educational & promotional material for physicians and their patients.• Published Article: Arthritis Research and Therapy “Patient-leveled pooled analysis of adjudicated GI outcomes in Celebrex clinical trials.” 2013, January 8th

Baltimore, Maryland, Us

• Created Case Report Forms (CRF), and created Standard Operating Procedures (SOP) during lab’s inception• Performed RT-PCR, ELISA and Western Blot in a microbiology lab, translational research• Collaborated on data analysis and interpretation of matrix metalloproteinase expression in colonic epithelial cells• Investigated microRNA expression in IBD patient colonic epithelium, & it’s target MIP-2alpha.• Foundation for treatments like Natalizumab, which acts on α4-integrin, was the first such drug to be approved for Crohn's disease, but its use is limited due to the risk of progressive multifocal leukoencephalopathy.• Introduced to a real Cellular and Molecular Biology Laboratory and performed PCR, Western Blot, and Liquid Chromatography using sterile technique • Analysis of the expression of genetic markers in colonic epithelial cells of a patient with Inflammatory Bowel Disease (IBD = Crohns Disease & Ulcerative Colitis)

Bachelor Of Science - Bs, Molecular Biochemistry

Master Of Public Health - Mph, Biostatistics

Doctor Of Medicine - Md, Medicine